Full Text
The Full Text of this article is available as a PDF (49.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bansback N. J., Brennan A., Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2004 Nov 18;64(7):995–1002. doi: 10.1136/ard.2004.027565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brennan A., Bansback N., Reynolds A., Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2003 Jul 30;43(1):62–72. doi: 10.1093/rheumatology/keg451. [DOI] [PubMed] [Google Scholar]
- Hider Samantha L., Buckley Caitriona, Silman Alan J., Symmons Deborah P. M., Bruce Ian N. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol. 2005 Jan;32(1):11–16. [PubMed] [Google Scholar]
- Jobanputra P., Barton P., Bryan S., Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2002;6(21):1–110. doi: 10.3310/hta6210. [DOI] [PubMed] [Google Scholar]
- Kavanaugh A., St Clair E. W., McCune W. J., Braakman T., Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000 Apr;27(4):841–850. [PubMed] [Google Scholar]
- Keystone Edward C., Kavanaugh Arthur F., Sharp John T., Tannenbaum Hyman, Hua Ye, Teoh Leah S., Fischkoff Steven A., Chartash Elliot K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May;50(5):1400–1411. doi: 10.1002/art.20217. [DOI] [PubMed] [Google Scholar]
- Klareskog Lars, van der Heijde Désirée, de Jager Julien P., Gough Andrew, Kalden Joachim, Malaise Michel, Martín Mola Emilio, Pavelka Karel, Sany Jacques, Settas Lucas. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681. doi: 10.1016/S0140-6736(04)15640-7. [DOI] [PubMed] [Google Scholar]
- Kobelt G., Eberhardt K., Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004 Jan;63(1):4–10. doi: 10.1136/ard.2003.010629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
- Maetzel Andreas. Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary. J Rheumatol Suppl. 2005 Jan;72:51–53. [PubMed] [Google Scholar]
- Maetzel Andreas, Tugwell Peter, Boers Maarten, Guillemin Francis, Coyle Doug, Drummond Mike, Wong John B., Gabriel Sherine E., OMERACT 6 Economics Research Group Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol. 2003 Apr;30(4):891–896. [PubMed] [Google Scholar]
- Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
- Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
- Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
- Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
- van de Putte L. B. A., Atkins C., Malaise M., Sany J., Russell A. S., van Riel P. L. C. M., Settas L., Bijlsma J. W., Todesco S., Dougados M. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004 May;63(5):508–516. doi: 10.1136/ard.2003.013052. [DOI] [PMC free article] [PubMed] [Google Scholar]